Significant improvements in OS and RFS for older patients with AML
About 40-50% of older patients with AML attain complete remission (CR) with induction chemotherapy but the majority of them eventually relapse. At EHA 2021 Congress, Farhad Ravandi present new data from the QUAZAR AML-001-study. It shows significant improvements in OS and RFS with CC-486, an oral hypomethylating agent. Farhad Ravandi are professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center, Texas, USA.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.